Overview
Ethosuximide is a first-line anticonvulsant medication belonging to the succinimide class. Developed in the 1950s, it remains the gold standard for treating absence (petit mal) seizures due to its selective action on thalamic T-type calcium channels. The drug is listed on the WHO Essential Medicines List and is available in both generic and branded formulations (e.g., Zarontin). As a small organic molecule (C7H11NO2), ethosuximide demonstrates excellent bioavailability when administered orally, with peak plasma concentrations reached within 1-4 hours. Its therapeutic window is well-established, typically maintaining serum concentrations between 40-100 μg/mL for optimal efficacy while minimizing side effects.
Physical and Chemical Properties
Ethosuximide presents as a white to off-white crystalline powder with a faint characteristic odor. The compound exhibits stability under normal storage conditions but should be protected from prolonged exposure to light and humidity. Its relatively low melting point (64-65°C) makes it suitable for various pharmaceutical formulation processes. The drug demonstrates excellent solubility profiles, dissolving readily in water (1:5 ratio), ethanol (1:2), and chloroform (1:3). This property facilitates its use in both solid (tablets, capsules) and liquid (syrups) dosage forms. The pKa of ethosuximide is approximately 9.3, indicating weak acidic characteristics that influence its pharmacokinetic behavior.
Main Applications
Ethosuximide's primary clinical application is the management of absence seizures, achieving control in approximately 60-70% of cases as monotherapy. It is particularly effective in childhood absence epilepsy, where it demonstrates superior efficacy compared to valproate in some patient populations. The drug may be combined with other antiepileptics for mixed seizure types. Beyond neurology, research suggests potential applications in neuropathic pain management and as an adjunct in bipolar disorder treatment. However, these off-label uses require further clinical validation. In pharmaceutical manufacturing, ethosuximide serves as an active pharmaceutical ingredient (API) for both immediate-release and sustained-release formulations.
Safety and Storage
Ethosuximide is generally well-tolerated but requires careful handling in both clinical and industrial settings. Common adverse effects include drowsiness, dizziness, and gastrointestinal disturbances. Rare but serious reactions like Stevens-Johnson syndrome warrant immediate discontinuation. For bulk storage, maintain temperatures between 15-30°C in tightly sealed containers with desiccants. The compound shows stability for at least 36 months when stored properly. Industrial handlers should use appropriate PPE (gloves, masks) to prevent inhalation or dermal contact, though the compound poses low acute toxicity risk (LD50 >2000 mg/kg in rats).
B2B Procurement Guide
Pharmaceutical manufacturers should prioritize suppliers with cGMP certification and documented quality systems. Key procurement considerations include batch-to-batch consistency (≥99.5% purity), residual solvent levels (meeting ICH Q3C guidelines), and particle size distribution for formulation compatibility. Request comprehensive documentation including Certificate of Analysis (COA), Drug Master Files (DMF), and stability studies (ICH accelerated conditions). For international shipments, verify compliance with destination country regulations - USP for North America, EP for Europe, and JP for Japan. MOQs typically start at 25kg, with lead times of 2-6 weeks depending on supplier location and inventory status.
Related Manufacturers
- 主营：莪术二酮、人参皂苷rc、自制对照品、乙琥胺、淫羊藿次苷
- 主营：对照品、科研实验、试剂盒、乙琥胺、多糖、安石榴苷、儿茶素、绿原酸、尿石素、人参皂苷、花青素、维生素、异鼠李素、甘草系列、人参系列、补骨脂系列、雷公藤系列、黄芩系列、柴胡系列、丹参系列、酸枣仁系列、重楼系列、大黄系列、五味子系列、化合物、黄芪皂苷系列
- 主营：砷酸锂、白云石、水合物、苯甲酸乙酯、乙酰丙酮锌、对乙酰氨基苯酚、氮化锌、144205-68-5、二叔丁基、利多卡因、碳化钨钴、泛影葡胺、化合物库、1093222-27-5、羟基苯基、八钼酸铵、生化试剂、熊去氧胆酸、胆酸二水合、湿法云母粉、六氟磷酸盐、干法云母粉、苯碳酸甲酯、脱氧胆酸二水、氨基二琥珀酸